Front. Endocrinol.Frontiers in EndocrinologyFront. Endocrinol.1664-2392Frontiers Media S.A.10.3389/fendo.2019.00146EndocrinologyOriginal ResearchOutcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial TreatmentKlainMichele1PaceLeonardo2*ZampellaEmilia1MannarinoTeresa1LimoneSimona1MazziottiEmanuela1De SiminiGiovanni1CuocoloAlberto11Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II, Napoli, Italy2Dipartimento di Medicina, Chirurgia ed Odontoiatria Scuola Medica Salernitana, Università Degli Studi di Salerno, Salerno, Italy
Edited by: Alessandro Antonelli, University of Pisa, Italy
Reviewed by: Vasyl Vasko, Uniformed Services University of the Health Sciences, United States; Trevor Edmund Angell, Keck School of Medicine of USC, University of Southern California, United States
*Correspondence: Leonardo Pace lpace@unisa.it
This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Background: In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and 131I remnant ablation an empiric 131I therapy may be considered. However, outcome data after empiric therapy in did not show a clear evidence of improved survival. We assessed the efficacy of such empiric 131I therapy in patients with DTC and evaluated the long-term outcome.
Methods: A total of 100 patients with DTC showing raised Tg level during follow-up after thyroidectomy and 131I ablation were treated with a further 131I therapy (6.1 ± 1.7 GBq). Whole-body scan (WBS) was performed 5–7 days after therapy. Tg value at 12 months after 131I therapy was considered as an indicator of treatment response: ≤1.5 ng/ml complete remission (CR), >50% decrease partial remission (PR), higher than pre-therapy progression disease (PD), all other cases stable disease (SD). Patients were followed-up for 96 ± 75 months.
Results: After 12 months, 62% of patients were in CR, 16% in PR, 8% in SD, and 14% in PD. WBS was positive in 41% of patients and negative in 59% (P = NS). Among patients with local recurrences at WBS 89% showed either CR or PR, while 71% of patients with distant metastases were in SD or PD (P < 0.001). Distant metastases at WBS (P < 0.05), CR (P < 0.0001), and CR + PR (P < 0.0001) were predictors of both progression free survival and overall survival.
Conclusion: There is a beneficial effect of 131I therapy on outcome of patients with DTC treated on the basis of elevated Tg value. In these patients, survival is affected by achievement of CR or PR at 12 months evaluation after 131I therapy and by the presence of distant metastases at WBS.
differentiated thyroid carcinoma131I empiric therapyprognosisthyroglobulinwhole body scanIntroduction
Follow-up of patients with differentiated thyroid cancer (DTC) after total or near-total thyroidectomy and 131I remnant ablation is performed by assessment of thyroglobulin (Tg) levels, ultrasonography, and 131I diagnostic whole-body scan (d-WBS). The most reliable parameter for the detection of tumor recurrence is a raised Tg level, which suggests persistence or recurrence of viable tumor tissue (1–5). In these patients an empiric 131I therapy may be considered (6), although there is still no agreement on the cutoff value of serum Tg above which a patient should be treated with an empiric 131I dose. It has been reported that patients with stimulated serum Tg ≥ 5 ng/ml are unlikely to have a decline without therapy, while a high rate of subsequent structural recurrence has been reported (7, 8). In these patients, administration of high activity of 131I would have both a diagnostic and therapeutic intent. Actually, a decrease in Tg levels after empiric 131I therapy has been demonstrated in 56–63% of such patients and in 61% of them post-therapy 131I whole-body scan (t-WBS) was positive (9, 10). Yet, data on outcome after empiric therapy in this setting did not show a clear evidence of improved survival (11–13).
Therefore, the aims of this study were to assess the efficacy of a high-dose 131I therapy administered only on the basis of a raised serum Tg level in patients with DTC after initial treatment and to evaluate the long-term outcome.
Materials and MethodsStudy Population and Design
Among 1,115 patients with DTC treated with total or near-total thyroidectomy followed by 131I ablation between 1998 and 2006, those (n = 100) showing raised (i.e., >5 ng/ml) serum Tg level during follow-up were included in this retrospective study. The study protocol is outlined in Figure 1. After 131I ablation, L-thyroxine therapy for TSH suppression was performed in all patients according to the American Thyroid Association (ATA) guidelines (6). Results of 131I ablation were evaluated after 12 months by Tg assessment off L-thyroxine therapy, d-WBS and neck ultrasound. All patients underwent d-WBS while off L-thyroxine therapy for 3 weeks. Imaging was performed 48 h after administration of 250 MBq of 131I using a dual-head gamma camera (E.CAM, Siemens Medical Systems, Hoffman Estates, IL, USA) equipped with a high-energy, general purpose collimator and connected with a dedicated computer system. Exclusion criteria were: positive serum anti-Tg antibody and a d-WBS scan 12 months after 131I ablation demonstrating thyroid remnant or secondary lesions. Hence, all patients showed an excellent response after ablation (6). For empiric 131I therapy, L-thyroxine was discontinued for 20-30 days until the TSH augmented (≥25–30 mIU/l). At that time, Tg concentration was measured and 131I was administered (6.1 ± 1.7 GBq). Five to seven days later, t-WBS was performed.
Outline of the study protocol.
Since all patients had a negative d-WBS 12 months after 131I ablation, the presence of tracer uptake in the cervical region at t-WBS performed after empiric 131I therapy was considered as local recurrence, while uptake in other regions was considered as distant metastases. The presence of local recurrence and distant metastases was confirmed by additional imaging procedures such us ultrasound, computed tomography, and/or bone scintigraphy, as appropriate.
Response to 131I empiric therapy was evaluated by assessing the serum Tg level 12 months after empiric therapy. In particular, a Tg value ≤1.5 ng/ml was considered as complete remission (CR), a decrease >50% as partial remission (PR), a level higher than the pre-therapy value as progression disease (PD), while all other cases were considered to be in stable disease (SD) (14). Thereafter, patients were followed by Tg level determinations (on L-thyroxine and off L-thyroxine therapy, as requested) every 6–12 months and imaging procedures as appropriate, with a mean follow-up of 96 ± 75 months (range 12–276 months). Disease status was recorded at each evaluation time point. Progression free survival (PFS) was measured from the date of empiric 131I therapy to the first observation of progressive disease, relapse, need for additional therapy (i.e., 131I therapy or surgery), or death. Relapse of disease was defined as evidence of disease during follow-up after empiric 131I therapy by histological or imaging procedures, as appropriate, in patients with proven DTC and stimulated Tg levels > 2 ng/ml (15). Patients last known to be alive and progression free were censored at date of last contact. Overall survival (OS) was measured from the date of registration to the date of death.
Statistical Analysis
MedCalc Statistical Software version 13.1.2 was used for statistical analysis (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2014). Continuous data were tested for normal distribution by the D'Agostino-Pearson test. Data were expressed as mean ± standard deviation, median and range or as proportions, as appropriate. Differences among groups were analyzed by analysis of variance, Kruskal-Wallis test, or by chi square analysis, as appropriated. Univariate and multivariate logistic analyses were used to evaluate significant determinants of response to 131-I therapy. Univariate and multivariate analyses of clinical and imaging variables were performed using Cox proportional hazards regression. Only significant variables at univariate analysis were included in the multivariate model. Survival analysis was performed using Kaplan-Meier method and log-rank test. Survivors were censored at the time of last clinical control. A P < 0.05 was considered statistically significant.
Results
Among 100 patients (68 women and 32 men; mean age 46 ± 16 years, range 20–82 years) enrolled, 16 had follicular cancer, and 84 papillary cancer. At initial staging, after surgery and 131I ablation, 60 patients were in stage I, 10 in stage II, 23 in stage III, and 7 in stage IVa. According to the ATA risk stratification system, 43 patients were in low, 41 in intermediate, and 16 in high-risk group. t-WBS performed at 131I ablation was negative in 5 patients and showed tracer uptake in the cervical region (i.e., thyroid remnant) in 95 patients. Differently, d-WBS performed 12 months after 131I ablation was negative in all patients. t-WBS performed after empiric 131I therapy was negative in 59 patients and positive in 41. Among patients with positive scan, 27 presented local recurrence and 14 distant metastases (7 lung metastases, 4 bone metastases, and 3 both). Table 1 shows the characteristics of patients according to response to empiric 131I therapy after 12 months of treatment. Of all patients, 62 were in CR, 16 in PR, 8 in SD, and 14 showed PD. CR was evident in 67% of papillary DTC and in 37% of follicular DTC, PR in 17% of papillary DTC and in 13% of follicular DTC, SD in 7% of papillary DTC and in 13% of follicular DTC, PD in 10% of papillary DTC, and in 37% of follicular DTC (P < 0.01). A significant association (P < 0.001) between initial staging and response to empiric therapy was found, with the majority (83%) of patients in earlier stage (i.e., I and II) showing either CR of PR. Similarly, the response to empiric therapy was significantly (P < 0.01) associated with the initial ATA patients risk classification: 81% (35/43) of patients in low risk class showed either CR or PR. Pre-therapy Tg was higher in PD than in CR patients (Table 1). There was no statistical difference in the percentage of patients showing CR, PR, SD, and PD between negative and positive t-WBS (69, 15, 3, and 12% vs. 51, 17, 15, and 17%, respectively). However, when positive t-WBS were subdivided according to site of uptake, 89% of those with local recurrences showed either CR or PR, while 71% of patients with distant metastases at t-WBS were in SD or PD (Table 1), and this difference was statistically significant (P < 0.001). At multivariate logistic analysis, only these results of t-WBS were significant determinants of 131I therapy response, either CR or PR (odds ratio 0.32, 95% confidence interval 0.17–0.62, P < 0.001) (Table 2).
Characteristics of patients according to 131-I therapy response.
CR (n = 62)
PR (n = 16)
SD (n = 8)
PD (n = 14)
p-value
Age (years)
42 ± 16
53 ± 16
46 ± 19
52 ± 15
0.06
Female gender (n)
41
10
6
11
0.7
HISTOLOGY
Papillary (n)
56
14
6
8
<0.01
Follicular (n)
6
2
2
6
STAGE
I
45
6
3
6
<0.001
II
1
6
1
2
III
12
3
2
6
IV
4
1
2
0
ATA RISK GROUP
Low
24
11
2
6
<0.01
Intermediate
28
3
2
8
High
10
2
4
0
Time interval between therapy (months)
24 (12–240)
24 (12–96)
27 (12–96)
25 (12–96)
0.5
Pre-therapy Tg level (ng/ml) offa
13.5 (5–6,000)
56.8 (8–2,107)
60.5 (12–1,000)
62.2 (5–500)
<0.001
Administered 131-I activity (GBq)
3.7 (3.7–7.4)
5.2 (3.7–7.4)
5.5 (3.7–7.4)
5.2 (3.7–7.4)
0.09
POST-THERAPY WBS
Negative
41
9
2
7
<0.001
Local disease
18
6
2
1
Distant metastases
3
1
4
6
Data are presented as mean ± SD or median (range).
off L-thyroxine therapy.
Univariate and multivariate analysis of predictors of complete and partial remission after empiric 131-I therapy.
Univariate
Multivariate
Odds ratio (95% CI)
p-value
Odds ratio (95% CI)
p-value
Age
0.39 (0.14 – 1.06)
0.06
Female gender
0.56 (0.18 – 1.67)
0.06
Histology (papillary)
0.18 (0.06 – 0.58)
0.005
Tg pre-therapy off L-thyroxine therapy
1.0 (0.99 – 1.01)
0.8
Stage (I and II vs. III and IV)
0.41 (0.16 – 1.10)
0.08
ATA risk class (low vs. intermediate and high)
0.70 (0.26 – 1.18)
0.5
Time interval between therapy
1.0 (0.99 – 1.01)
0.7
Administered activity
1.0 (0.99 – 1.01)
0.8
t-WBS (positive)
0.39 (0.15 – 1.02)
0.06
t-WBS (distant metastases)
0.32 (0.17 – 0.62)
<0.001
0.32 (0.17 – 0.62)
<0.001
CI, confidence interval.
During subsequent follow-up (mean 96 ± 75 months, range 12–276) 38 patients showed progressive disease or relapse and 6 died of thyroid cancer (Figure 2). Of the 38 patients with progressive disease or relapse, 13 (34%) were in CR, 10 (26%) in PR, 4 (11%) in SD, and 11 (29%) had PD at 12 months evaluation after empiric 131-I therapy (P < 0.0001). Four of these 38 patients underwent surgery for lymph node recurrence and 34 further therapies with 131I (one additional therapy in 18 patients, two additional therapies in 11 patients, and three or more therapies in 9 patients). Of these latter 34 patients, 18 were retreated for PD (positive t-WBS after empiric 131I therapy) and 16 for persistent high Tg levels. Of the 38 patients with progressive disease or relapse 17 (45%) were in stage I, 9 (24%) in stage II, 8 (21%) in stage III, and 4 (10%) in stage IVa (p < 0.05). Moreover, of the same 38 patients 7 (18%) were in the ATA high risk group, 12 (32%) in the intermediate risk group, and 19 (50%) in the low risk group (P = 0.06). Of the 6 patients who died, 1 showed PR, 2 showed PD, and 3 were in SD at 12 months evaluation after empiric therapy (P = 0.6). Of the same 6 patients, 2 (33%) were in stage I, 3 (50%) in stage III, and 1(17%) in stage IV (P = 0.6). Also, 5 (83%) patients were in the ATA intermediate risk group and 1 (17%) in the high-risk group (P = 0.2).
Response to empiric 131I therapy: assessment at 12 months and subsequent follow-up. CR, complete remission; PR, partial remission; SD, stable disease; PD, progression disease.
Fifty percent of patients with a positive t-WBS and 32% of those with a negative t-WBS showed progressive disease or relapse (P < 0.05). In particular, 46% of patients with regional uptake at t-WBS and 73% of those showing distant metastases had progressive disease or relapse. Of the 6 patients who died during follow-up, none was in CR at 12 months evaluation after empiric therapy and 4 had a positive t-WBS (3 with distant metastases). At univariate analysis, distant metastases (P < 0.05), CR (P < 0.0001) and CR + PR (P < 0.0001) were predictors of PFS (Table 3). Figure 3 shows the PFS at Kaplan-Meier analysis according to presence of distant metastases, CR and CR + PR. At multivariate analysis, only CR was retained in the model (P < 0.0001). At univariate analysis, distant metastases (P < 0.05), CR (P < 0.0001), and CR + PR (P < 0.0001) were significant predictors of OS (Table 3). Figure 4 shows the OS at Kaplan-Meier analysis according to presence of distant metastases, CR and CR + PR. At multivariate analysis, only CR or PR was retained in the model (P < 0.0001).
Univariate predictors of progression free survival and overall survival based on clinical and imaging data.
Progression free survival
Overall survival
χ2
p-value
χ2
p-value
Age
1.0
0.3
0.1
0.9
Female gender
0.9
0.3
0.2
0.7
Histology (papillary)
1.5
0.2
0.7
0.5
Tg pre-therapy off L-thyroxine therapy
0.1
0.9
0.1
0.8
Stage (I and II vs. III and IV)
1.9
0.2
3.8
0.5
ATA risk class (low vs. intermediate and high)
0.2
0.6
8.1
<0.01
Time interval between therapy
0.9
0.7
0.4
0.5
Administered activity
1.9
0.2
0.4
0.5
t-WBS (positive)
3.3
0.06
2.3
0.1
t-WBS (distant metastases)
4.9
<0.05
5.1
<0.05
Complete remission
48.9
<0.0001
15.8
<0.0001
Complete remission + partial remission
32.0
<0.0001
15.5
<0.0001
Progression-free survival (PFS) by Kaplan-Meier analysis and log-rank test based on the presence of distant metastases at therapeutic 131I whole body scan (WBS) (A) complete response at 12 months evaluation after 131I therapy (B) complete response + partial response at 12 months evaluation after 131I therapy (C). t-WBS, therapeutic 131I WBS; DM, distant metastases; CR, complete remission; PR, partial remission.
Overall survival (OS) by Kaplan-Meier analysis and log-rank test based on the presence of distant metastases at therapeutic 131I whole body scan WBS (A) complete response at 12 months evaluation after 131I therapy (B) complete response + partial response at 12 months evaluation after 131I therapy (C). t-WBS, therapeutic 131-Iodine WBS; DM, distant metastases; CR, complete remission; PR, partial remission.
Discussion
In this retrospective follow-up study of patients treated with 131I empiric therapy on the basis of elevated Tg, post-therapy WBS was positive in 41% of the patients and complete biochemical remission 12 month after 131I empiric therapy was observed in 62% of the entire population. Results of therapy were not related to age and gender, while patients with lower values of pre-therapy Tg achieved more frequently CR. Moreover, remission was more probable in patients in earlier stage of disease at presentation and in those in low-risk class as well as in patients not showing distant metastases at t-WBS performed after empiric 131I therapy. Both PFS and OS were better in patients showing remission at 12 months evaluation after empiric therapy as in those not showing distant metastases at t-WBS performed after empiric therapy.
According to ATA guidelines, 131I therapy is suggested in patients with elevated serum Tg levels when imaging did not show a tumor source amenable to directed therapy (6). While more than 50% of patients treated do have a reduction in Tg values (10, 16–18), improved survival has not been demonstrated (11–13). A large variability in percentage of patients showing positive t-WBS (ranging from 43 to 94%) has been reported, with a mean value of 61% (10, 19). On the other hand, the percentage of patients treated with 131I showing Tg values significantly decreased or undetectable Tg ranges from 20 to 72%, with a mean of 56% (10). No statistically significant difference in CR between patients with positive and negative t-WBS has been previously reported (11, 13, 16).
The results of our study confirm that 131-I therapy administered on the basis of elevated Tg is effective independently from the results of t-WBS. However, it should be noted that while 67% of patients with loco-regional uptake had CR, only 21% of those showing distant metastases achieved CR. It has been reported that in patients with structurally identifiable metastatic DTC 131I therapy failed to cause disease regression or conversion from progressive to SD in any patient (20). Moreover, serum Tg levels after 131I therapy decreased more frequently in patients with micro-metastases than in those with macro-metastases (12, 17), and CR has been observed only in 24.2% of patients with lung metastases (21).
The rationale of empiric 131I therapy is both diagnostic and therapeutic. However, it has been reported a relatively low rate of detection of pathological uptake mainly in patients with negative WBS at ablation (22, 23). The percentage of patients with positive t-WBS in our study is 41%, in the range reported in the literature (9, 10), and it should be noted that in our study the results of t-WBS at ablation have not been considered among the inclusion criteria, while a negative d-WBS after 131I ablation was one of the inclusion criteria.
No definite data on outcome of patients treated with 131I therapy on the basis of elevated Tg are present in the literature (11–13). In 42 patients with negative WBS and elevated Tg treated with a therapeutic dose of 131I and followed-up for 6.7 ± 3.8 years, Pacini et al. (11) found resolution of 131I uptake in 88.8% of lung metastases and in 61.1% of cervical node metastases. In the subgroup of patients with negative t-WBS (n = 12) one patient died (11). Fatourechi et al. (12) showed in 24 consecutive patients treated with 131I therapy (follow-up 6–33 months) that progression was evident in 13 patients with macro-metastases and 5 died of thyroid cancer, while the disease remained stable in 7 patients with micro-metastases. However, no statistical survival analysis was performed in these studies (11, 12). In 56 patients with DTC with negative WBS and increased serum Tg, van Tol et al. (13) found a 5-year survival of 100% in the group with positive t-WBS and of 76% in the group with negative t-WBS (P < 0.001). It should be noted that in that study a higher percentage of patients with positive t-WBS reached remission as compared to those with negative t-WBS (64 vs. 36%, P = 0.06) (13).
In our study we evaluated long-term follow-up in a group of 100 patients. Our results show a better PFS in patients without distant metastases at t-WBS and in patients showing CR or PR at 12 months evaluations after 131I therapy; moreover, OS was better in patients without distant metastases at t-WBS and in patients showing CR or PR at 12 months evaluations after 131I empiric therapy. Since the need for additional therapy was one of the end points for PFS, it is not surprising to find the presence of distant metastases at t-WBS to be a significant predictor. On the other hand, also OS is predicted by the presence of distant metastases at t-WBS.
Besides its retrospective observational nature, our study had other limitations. A similar control cohort in which 131I therapy was not performed is not available. Moreover, in a retrospective analysis the ability to discern certain treatment effects is limited by small sample size and limited number of events. Therefore, a randomized controlled study, with a larger cohort of patients, is needed to assess the prognostic impact of the empiric 131I therapy in patients with raised Tg values.
Conclusions
The findings of this study suggest a beneficial effect of 131I therapy on the outcome of patients treated on the basis of elevated Tg value. However, survival is strongly affected by the achievement of remission, either complete or partial, at 12 months evaluation after 131I therapy and by the presence of distant metastases at t-WBS.
Data Availability
The datasets generated for this study are available on request to the corresponding author.
Ethics Statement
This study follows the principles expressed in the Declaration of Helsinki. All study participants waived informed consents owing to the retrospective analysis, and the study design was approved by the appropriate ethics review boards.
Author Contributions
MK, LP, and AC contributed conception and design of the study. EM, GD, and TM collected the data and organized the database. LP and SL analyzed the data. MK and EZ wrote the first draft of the manuscript. All authors contributed to the final version of the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
ReferencesOzataMSuzukiSMyamotoTLiuRTFierro-RenoyFDegrotLJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. (1994) 79:98–105. 8027262DurenMSipersteinAESheenWDuhQYMoritaEClarkOH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high and low-risk patients. Surgery. (1999) 126:13–9. 10.1067/msy.1999.9884910418587PaciniFPincheraA. Serum and tissue thyroglobulin measurements: clinical applications in thyroid disease. Biochimie. (1999) 81:463–7. 10.1016/S0300-9084(99)80096-0MazzaferriELRobbinsRJSpencerCABravermanLEPaciniFWartofskyL. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. (2003) 88:1433–41. 10.1210/jc.2002-02170212679418PaciniFCapezzoneMEliseiRCeccarelliCTadeiDPincheraA. Diagnostic 131-I whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. (2002) 87:1499–501. 10.1210/jcem.87.4.8274HaugenBRAlexanderEKBibleKCDohertyGMMandelSJNikiforovYE. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. (2016) 26:1–133. 10.1089/thy.2015.002026462967PadovaniRPRobenshtokEBrokhinMTuttleRM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. (2012) 22:778–83. 10.1089/thy.2011.052222780333YimJHKimEYBaeKWKimWGKimTYRyuJS. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid. (2013) 23:58–63. 10.1089/thy.2011.048722973946MaCXieJKuangA. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?J Nucl Med. (2005) 46:1164–70. Available online at: http://jnm.snmjournals.org/content/46/7/1164.long16000286ChaoM. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin Oncol. (2010) 22:438–47. 10.1016/j.clon.2010.05.00520561773PaciniFAgateLEliseiRCapezzoneMCeccarelliCLippiF. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. (2001) 86:4092–7. 10.1210/jcem.86.9.783111549631FatourechiVHayIDJavedanHWisemanGAMullanBPGormanCA. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. (2002) 87:1521–6. 10.1210/jcem.87.4.837311932275van TolKMJagerPLde VriesEGPiersDABoezenHMSluiterWJ. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol. (2003) 148:589–96. 10.1530/eje.0.148058912773129PaceLKlainMAlbaneseCSalvatoreBStortoGSoricelliA. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging. (2006) 33:179–83. 10.1007/s00259-005-1929-216205897HovensGCStokkelMPKievitJCorssmitEPPereiraAMRomijnJA. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab. (2007) 92:2610–5. 10.1210/jc.2006-256617426094KohJMKimESRyuJSHongSJKimWBShongYK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol. (2003) 58:421–7. 10.1046/j.1365-2265.2003.01733.x12641624KabasakalLSelcukNAShafipourHOzmenOOnselCUsluI. Treatment of iodine-negative thyroglobulin positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging. (2004) 31:1500–4. 10.1007/s00259-004-1516-y15232654SinhaPConradGRWestHC. Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome. Anticancer Res. (2011) 31:2109–12. Available online at: http://ar.iiarjournals.org/content/31/6/2109.long21737629KalenderEUmu ElbogaUÇelenYDemirHSahinESeyhan KaracavusS. Empiric 131I treatment of high thyroglobulin levels in differentiated thyroid carcinoma after remnant ablation. Acta Med Mediterranea. (2014) 30:503–7. Available online at: http://www.actamedicamediterranea.com/archive/2014/medica-2/empiric-sup131supi-treatment-of-high-thyroglobulin-levels-in-differentiated-thyroid-carcinoma-after-remnant-ablationSabraMMGrewalRKTalaHLarsonSMTuttleRM. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid. (2012) 22:877–83. 10.1089/thy.2011.042922827641SongHJQiuZLShenCTWeiWJLuoQY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. (2015) 173:399–408. 10.1530/EJE-15-029626104753KimWGRyuJSKimEYLeeJHBaekJHYoonJH. Empiric high dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab. (2010) 95:1169–73. 10.1210/jc.2009-156720080852RosarioPWMouraoGFdos SantosJBCalsolariMR. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?Thyroid. (2014) 24:533–6. 10.1089/thy.2013.042724067080